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The multidrug-resistance-1 (MDR1) gene encodes an ATP-dependent efflux 
transporter that is highly expressed in the colon. In mice, loss of MDR1 function 
results in colitis with similarities to human inflammatory bowel diseases (IBD). Here, 
we show that MDR1 has an unexpected protective role for the mitochondria where 
MDR1-deficiency results in mitochondrial dysfunction with increased mitochondrial 
ROS (mROS) driving the development of colitis. Exogenous induction of mROS 
accelerates, whilst inhibition attenuates colitis in vivo; these effects are amplified in 
MDR1-deficiency. In human IBD, MDR1 is negatively correlated to SOD2 gene 
expression required for mROS detoxification. To provide direct evidential support, we 
deleted intestinal SOD2 gene in mice and showed an increased susceptibility to 
colitis. We exploited the GWA datasets and found many (~5%) of IBD susceptibility 
genes with direct roles in regulating mitochondria homeostasis. As MDR1 primarily 
protects against xenotoxins via its efflux function, our findings implicate a distinct 
mitochondrial toxin + genetic susceptibility interaction leading to mitochondrial 
dysfunction, a novel pathogenic mechanism that could offer many new therapeutic 
opportunities for IBD. 
  
Introduction 
Inflammatory bowel diseases (IBD) are complex immune-mediated conditions that 
can be subclassified into the clinically distinct entities of Crohn’s disease (CD) and 
ulcerative colitis (UC) 1,2. Both are debilitating relapsing inflammatory conditions, 
which affect an estimated 4 million people in the United States and Europe with 
increasing prevalence in the developing world 3. CD is characterised by 
discontinuous aphthous mucosal ulcerations and inflammation occurring most 
commonly in the distal small intestine (ileum) and variably across the intestinal tract2. 




UC affects only the large bowel (colon) in a confluent manner and is characterised by 
superficial mucosal inflammation4. Increasingly evident both in clinical and molecular 
studies is the concept that IBD involves multiple distinct and also, common 
pathogenic mechanisms. The powerful genomewide association (GWA) studies 
implicate more than 200 genetic susceptibility loci including genes in biological 
pathways regulating innate (e.g. NOD2 and autophagy) and adaptive (e.g. Th17, 
MHC) immune responses, cytokine production, lymphocyte activation and bacterial 
response5,6. 
 
One major mechanistic theme that is shared between UC and CD is the role of 
intestinal epithelial dysfunction and injury7. The intestinal epithelium is uniquely in 
contact with high concentrations of bacteria with their metabolic products, immune-
active ligands, damage-associated molecular products (DAMPs), xenobiotics and 
environmental toxins8. Thus, a central component of IBD pathogenesis is the de-
regulation of protective mechanisms that maintain cellular homeostasis and resultant 
epithelial dysfunction. MDR1 is a key mediator of one such mechanism9 by actively 
extruding more than 4000 diverse products, including xenotoxins, out of the 
intracellular environment10. MDR1 belongs to the ATP-binding cassette, ABC-
transporter family of transmembrane transporters. These proteins bind ATP and use 
the energy to drive the transport of various molecules across all cell membranes. 
Genetic variations in this family of genes contribute to several human disorders 
including cystic fibrosis, neurological diseases, retinal degeneration, anaemia, 
cholesterol and bile transport defects9.  
 
Epithelial cells of the distal intestinal tract have very high MDR1 expression reflecting 
the importance of its cytoprotective role at the gut luminal interface 11. In the mouse, 




the mdr1a gene encodes PgP170. Constitutive genetic deletion of this gene results in 
chronic spontaneous colitis as the mutants age with ~50% penetrance when >6 
months of age12. Interestingly, the mdr1a-deficient mice display no other 
spontaneous clinical phenotype, underlining the dominant physiologic role of mdr1a 
in the gut. Its importance in colonocytes is further highlighted by the lack of rescue 
from colitis when mdr1a-deficient mouse were reconstituted with mdr1a+ bone 
marrow stem cells12. In human IBD, several studies have shown a downregulation of 
intestinal MDR1 expression13,14. MDR1 has been linked to IBD in early human 
candidate genetic studies with disease-associated variants associated with low 
MDR1 expression15. These findings implicate the loss of MDR1 function as a 
contributory factor in the pathogenesis of IBD.  
 
Although an underlying increase in intestinal permeability is considered as the 
dominant factor for the development of mdr1a-deficient colitis, the preceding steps 
leading to this late stage are not fully clarified16. In this study, we show for the first 
time that MDR1 confers a protective role to the gut epithelial mitochondria and that 
MDR1 deficiency results in mitochondrial dysfunction driving the development of 
colitis. The mitochondria play a key role in many physiologic processes such as 
energy production, regulation of cell death and immune response. Given that MDR1 
is critically positioned at the interface between mitochondria and the luminal 
environment, this protective mechanism opens up a fresh perspective in how de-
regulation of mitochondria homeostasis influences the development of colitis.  
 
  





Mdr1a-deficient colonic epithelium shows an accumulation of damaged 
mitochondria 
Using transmission electron microscopy, we showed that the mdr1a-deficient mice 
displayed a preferential accumulation of damaged and degenerating mitochondria in 
colonic epithelial cells (CECs) in the inflamed colon (Fig 1a). CECs harbouring these 
mitochondrial abnormalities were found in higher frequencies in mdr1a-deficient mice 
compared to non-inflamed colon, ileum and liver in wild type (WT) mice (14% vs. 
<2% overall frequency) (Figs 1b and S1a). These features were not present in il10-
deficient mice CECs, a spontaneous chronic colitis control group with a defined 
inflammatory mechanism17 (Fig S1b) and only in necrotic CECs during acute 
dextran-sulphate sodium colitis (DSS). Immunohistochemistry analysis of mdr1a-
deficient colons revealed increased colonic epithelial p62, PTEN-induced kinase 1 
(PINK1) and superoxide dismutase-2 (SOD2) staining (Fig 1c). p62 is a ubiquitin-
binding protein that promotes autophagic degradation of protein aggregates 
recognises damaged mitochondria and recruits them to the isolation membrane 
through its interaction with LC318. PINK1 is involved in specific autophagic clearance 
of damaged mitochondria (or mitophagy) 19; whereas SOD2 plays a role in 
detoxifying mitochondrial reactive oxygen species (ROS). Furthermore, isolated 
CECs confirmed higher p62, increased microtubule-associated protein 1 light chain 
3-β, LC3-I to phosphatidylethanolamine (PE)-conjugated or LC3-II ratio indicative of 
heightened autophagy; and parkin expression in mdr1a-deficiency (Fig S2a). Parkin 
translocates to mitochondria upon dissipation of mitochondria membrane potential 
and cooperates with PINK1 during mitophagy. CEC voltage-dependent anion 
channel (VDAC) expression and mitochondria DNA were similar to WT, suggesting 
that these changes were not due to changes in mitochondria content (Figs 1c and 




S2b). Mitochondria isolated from mdr1a-deficient CECs were more sensitive to 
mitochondrial membrane damage by carbonyl cyanide m-chorophenyl hyrdrazone, 
CCCP, a known damaging agent (Fig 1d). Furthermore, we detected increased 
circulating plasma mitochondrial DNA, a known inflammatory DAMP in mdr1a-
deficient mice with colitis (Fig 1e). The mdr1a-deficient colons have increased 
epithelial cell turnover and death respectively (Figs S2c, d). MDR1-deficient mice 
exhibited clear evidence of colonic epithelial mitochondrial damage with increased 
epithelial dysfunction and cell-death. 
 
MDR1 deficiency results in mitochondria dysfunction 
To study the functional consequence of MDR1 deficiency on the mitochondria, we 
investigated the cellular energetics of primary colonic explants of mdr1a-/- and WT 
mice. We found lower basal O2 consumption rate (OCR) in mdr1a
-/- colon consistent 
with impaired mitochondrial function and energy production (Figs 2a). We further 
knocked down MDR1 expression in vitro by transducing short hairpin MDR1 
(shMDR1) in the human T84 CEC cell line (Figs S3a). Although we found no 
differences in OCR (Figs S3b), MDR1 deficiency in T84 CECs resulted in lower 
spare respiratory capacity (SRC) (Fig 2b). SRC is the extra mitochondrial capacity 
available in a cell to produce energy under conditions of increased work and stress 
and is thought to be important for long-term cell survival and function 20. 
Dysfunctional or damaged mitochondria produce increased levels of ROS and the 
mitochondria are the major source of ROS for most cells21. In line with our 
observations in mdr1a-deficient mouse CECs, we found increased levels of mROS in 
shMDR1 T84 CECs at baseline (Fig 2c); and following artificial induction with 
rotenone and antimycin by fluorescence of MitoSOX (a mitochondrial superoxide 
indicator) (Fig 2d). Furthermore, we showed that MDR1-knockdown resulted in 




higher p62 and SOD2 protein expressions following rotenone treatment in shMDR1 
CECs (Fig S3c). We transfected LC3-GFP and found reduced autophagy (Fig 2e); 
and LC3-II protein after inhibition of its degradation by bafilomycin (Fig S3d) in 
shMDR1 relative to shCtrl CECs. This suggests a depressed clearance that 
compounds mitochondria dysfunction. Degenerating mitochondria in CECs are 
notably present in mice models with primary autophagy (Irgm and Atg16l1)22,23, 
secondary autophagy impairments due to defective ER-stress 24 and NLRP6 
inflammasome activity 25. Our data collectively show that loss of MDR1 results in 
mitochondria dysfunction with impaired bioenergetics, increased mROS production 
and perturbed autophagic clearance.  
 
Experimental induction of colonic mitochondria ROS influences the 
development of colitis in MDR1a-deficiency  
We then sought to investigate if induction of mROS can accelerate the development 
of colitis in mdr1a-deficiency. We developed an in vivo protocol to test this further by 
directly administrating rotenone with low dose DSS (0.25%) into the colon of mdr1a-
deficient and WT mice. We chose rotenone to specifically focus on the effects of 
mROS and to test its early effects prior to full induction of DSS colitis. Rotenone is 
primarily an inhibitor of mitochondrial complex I of electron transport chain which 
results in increase mROS production and at higher doses, cellular bioenergetic 
deficit26. Rotenone is a well-described triggering factor for rodent models of 
Parkinson’s disease and is administered systemically (by injection) and/or orally27. 
Given that direct colonic administration in vivo is a new approach, we titrated the 
colonic rotenone concentration to 100µM (equating to ~1mg/kg) without systemic ill 
effects, notably respiratory, neurological and motor deficits (Fig S4a). Drug dosing 
data derived from rodent rotenone-induced Parkinson’s disease ranged between 2.5-




15mg/kg systemically to 0.25-100mg/kg orally26 with increased mortality is observed 
in the former approach. Within 24 hours of 100µM rotenone administration, we found 
that this is sufficient to trigger increased leukocyte infiltration and colitis in mdr1a-
deficient mice, which are not present in WT mice (Figs S4b, c) associated with 
increased CEC death in mdr1a-deficient colon (Figs S4d, e). We expanded our 
protocol where we directly administered 500µl of 100µM of rotenone 3 times/week 
over 4 weeks in the absence of DSS (Fig 3a). In mdr1a-deficient mice with no prior 
evidence of colitis, we found that this accelerated the onset of colitis compared to 
vehicle (Fig 3b, c). In mdr1a-deficiency, rotenone-treated mice have more severe 
colitis compared to the vehicle group (Fig 3d-f). Isolated CECs from rotenone-treated 
mdr1a-deficient mice have higher pro-inflammatory il6 and tnf-α gene expressions 
(Fig S4f). In addition to triggering spontaneous colitis, exogenous induction of 
mucosal mROS using rectal rotenone treatment (Fig 3g) rendered the mdr1a-
deficient mice more susceptible to acute DSS colitis exhibiting more severe clinical 
and histologic evidence of inflammation (Fig 3h-j). To investigate the effects of 
rotenone on the epithelial barrier, we further showed that shMDR1 compared to 
shCtrl CECs have an increased sensitivity to rotenone, CCCP and cisplatin-induced 
cell death (Figs S5a, b) and displayed an increased loss of barrier function as 
measured by transepithelial electric resistance following culture with rotenone (Fig 
S5c). In line with our in vivo data, we also showed that mROS-induced by rotenone 
triggered increased colonic epithelial IL-8 production induced by flagellin and 
bacterial CpG (these ligands chosen as our T84 CECs express TLR5 and TLR9) (Fig 
S6d), indicating that mROS triggers CEC-death and innate inflammatory responses. 
Collectively, these data suggest that abnormal mucosal mROS driven by an 
exogenous trigger can influence the onset and severity of colitis in a genetically 
susceptible host, in this respect, MDR1-deficiency.  





Inhibition of mitochondria ROS effects attenuates and promotes recovery from 
colitis in vivo 
Next we investigated whether inhibiting the effects of mROS can prevent or attenuate 
the development of colitis. Mitoquinone (MitoQ) is a mitochondrial specific antioxidant 
with coenzymeQ10 covalently attached to a triphenylphosphonium molecule, which 
selectively accumulates within the mitochondria. MitoQ protects the mitochondria 
membrane from mROS-induced lipid peroxidation and acts as a ROS-scavenger28. 
We first investigated the effect of mROS inhibition in mdr1a-deficient chronic colitis. 
Here, we tested the effects of colonic MitoQ (10µM), rotenone and vehicle only in 
mdr1a-deficient mice with clinical evidence of chronic colitis (10-12 weeks old, all 
with chronic diarrhoea)  (Fig 4a). Colonic MitoQ improved colitis in mdr1a-deficient 
mice (Figs 4b-d, S6a). In contrast to earlier data from mdr1a-deficient mice with no 
colitis, rotenone surprisingly, did not further exacerbate chronic colitis. We think this 
may be due to the intrinsic nature of mdr1a-deficient colitis model where the main 
driving factor is increased barrier permeability. Hence, colonic mitochondrial 
dysfunction in this setting acted as a triggering factor and once barrier function was 
compromised resulting in colitis, rotenone has a lesser role to worsen colitis in this 
model. Here, the histologic severity scores in both rotenone and control groups were 
8 and 9.5 respectively out of the maximal score 12. The high baseline made it difficult 
to test for an exacerbating role for rotenone. In acute DSS-colitis, colonic MitoQ 
delayed the onset in mdr1a-deficient mice (Fig 4f) and significantly attenuated colitis 
in WT mice (Figs 4g, S6b). In both settings, there were histologic improvements in 
the severity of colitis (Fig 4h). We also showed that MitoQ improved clinical recovery 
following 5 days of DSS challenge (Figs 4i, S6c). In this setting, we tested only WT 
mice, as mdr1a-deficient mice were too unwell after DSS-induction. Two recent 




studies corroborate the protective effects of MitoQ in acute DSS colitis (although via 
oral route) 29,30. Inhibiting the effects of mROS is therefore beneficial in acute and 
chronic colitis as well as during the recovering phase of colitis.   
 
MDR1 and SOD2 genes are differentially expressed in human IBD and 
intestinal epithelial specific deletion of SOD2 leads to increased susceptibility 
to experimental colitis 
To further investigate the role of MDR1 and mROS in human IBD, we performed an 
in silico analysis of our IBD colonic microarray dataset (Gene Expression Omnibus 
GSE11223 and GSE20881) derived from a cohort of 67 individuals with UC, 53 with 
CD, 14 non-IBD colitis and 31 healthy controls13,31. Colonic gene microarray 
expression data were available from 118 inflamed IBD, 110 non-inflamed IBD and 50 
healthy non-IBD colonic biopsies. In addition to significant downregulation of MDR1 
expression in inflamed vs. non-inflamed IBD intestinal biopsies and inflamed IBD vs. 
healthy non-IBD intestinal biopsies (p<0.0001 and 0.0003 respectively); we 
interestingly found differential expression of SOD2 expression (upregulated) in both 
analyses (p<0.001 and 0.0002) (Fig 5a, b).  MDR1 negatively correlated with SOD2 
(r= -0.47, p<0.0001) in line with our earlier findings in mdr1a-deficient mice and 
shMDR1 CECs (Fig 5c). It is essential to determine whether primary ROS-mediated 
mitochondria dysfunction acts causally to promote the development of colitis. 
Furthermore, there may be factors such as variability in tissue penetration and 
retention that cannot be completely accounted for in the colonic rotenone exposure 
model. Therefore we genetically deleted the SOD2 gene from the intestinal 
epithelium by crossing SOD2floxed/floxed mice with mice expressing Cre-recombinase 
under the control of the intestinal-epithelial-specific villin promoter to SOD2IEC-KO mice 
(Fig 5d). Constitutive deletion of SOD2 gene in mice resulted in death early after 




birth from cardiac and liver failure32. In our study, SOD2IEC-KO mice were born in 
normal Mendelian ratio and had no overall abnormalities in the morphology of ileum 
and colon.  Although they did not exhibit spontaneous colitis, SOD2IEC-KO developed 
more severe colitis following DSS treatment compared to SOD2floxed/floxed littermates 
(Fig 5e-g). Our data in SOD2IEC-KO mice provides evidential support for the loss of 
mitochondrial homeostasis in CECs as a specific factor in determining susceptibility 
to colitis. 
 
Associations of genes regulating mitochondrial function with human IBD 
Finally, to demonstrate clinical relevance of mitochondrial dysfunction as a new 
mechanistic factor in IBD, we exploited data from the latest meta-analysis of GWA 
studies of all European ancestry IBD patients vs. European controls (22,575 CD, 
20,417 UC and 53,536 controls) 6.  The most significant loci in the regions of ABCB1 
(encoding MDR1) and SOD2 genes showed associations with p=3.19 x 10-3 and 3.04 
x 10-3 respectively (below genome-wide significance). We performed an independent 
unbiased analysis (using GO term for mitochondria, GO:0005739 using the 
Mitominer program http://mitominer.mrc-mbu.cam.ac.uk/release-3.1) and identified 
29 (5.0%) additional genes involved in mitochondria function within the subset of 574 
(out of total 22 353) genes within 100kb of a genome-wide significant IBD locus from 
the same meta-analysis dataset above (Table S1). The top three positional 
candidate gene associations are: SLC25A28 (p=1.70 x 10-26) encoding mitoferrin-2, 
VARS encoding valine-tRNA ligase (p=4.83 x 10-26) and RNF5 (p=9.47 x 10-24) 
encoding E3 ubiquitin-protein ligase RNF5 are involved in mitochondria iron, tRNA 
transport and ubiquitination respectively33-35. Notable also, are the associations of the 
HSPA1-A, -B and –L (p=1.88 x 10-23) genes that encode the heat shock protein 70, 
which is integrally involved in the mitochondria unfolded protein responses (mtUPR), 




crucial for mitochondria protein homeostasis and biogenesis36. This suggests that the 




In this study, we define a key mitochondrial protective mechanism conferred by 
MDR1. Here, we present clear evidence of increased mitochondrial damage and 
consequential dysfunction following MDR1-deficiency with increased susceptibility to 
colitis driven by mitochondrial dysfunction in vivo. We therefore highlight a cogent 
model to further support mitochondrial dysfunction as an important mechanistic 
component in the pathogenesis of IBD (reviewed by Novak and Mollen) 37. We show 
conceptually that at the dynamic colonic mucosal interface in particular, mitochondria 
homeostasis requires tight regulation to prevent the deleterious downstream effects 
on epithelial integrity, activation of pro-inflammatory responses and release of 
mitochondria DAMPs as bona fide inflammatory triggers. The mitochondria 
participate in a broad range of innate responses to viral, bacterial and cellular 
damage38. Recently mitochondria have an increasingly recognized role in 
inflammation38 and are implicated in human diseases with underlying inflammatory 
pathologies, such as diabetes39, multiple sclerosis40, lung fibrosis41 and 
cardiovascular disease42.  
 
Our data suggest an intricately linked picture, where MDR1 protects against 
damaging mitochondrial factors arising from the luminal environment via its efflux 
properties in addition to exerting an influence on key homeostatic responses such as 
energy production and autophagy. The compositional factors within the lumen in this 
context; and alternatively, mechanisms that affect the functionality of MDR1 have not 




yet been studied in detail. As an ATP-dependent efflux transporter, gut energy 
deficiency is a likely important factor. In the colon, mitochondria rely on the gut 
microbiota and their production of short chain fatty acid for energy 43 and CEC 
energy deficiency has been previously purported to be an IBD mechanism. Mouse 
lines with mitochondria genomic variants linked to high ATP production are protected 
against induced colitis 44. Whilst analysis of cellular bioenergetics in primary explants 
showed impairment in energy production, our in vitro CEC data indicate a more 
modest effect without the contribution of the luminal flora, with decreased CEC spare 
respiratory capacity in the presence of diminished MDR1 activity. The lack of 
baseline OCR differences ex vivo and in vitro may reflect fundamental differences in 
genetic knock-down rather than knock-out, inherent bioenergetic properties of colonic 
'cancer' cell line and in vitro conditions that provided a more stable environment for 
mitochondrial function. In mouse, colonisation of specific gut commensals can 
influence the level of MDR1 gene expression45. Hence, it is conceivable that a 
primary effect of MDR1-deficiency on mitochondrial bioenergetics is potentiated by 
factors present in the luminal environment in the colon, chiefly the microbiota.  In 
IBD, high levels of mitochondria damage, notably within the electron transport chain 
have been shown in CECs 46 and the resident luminal microbiota are strongly 
implicated in the pathogenesis of IBD8.  
 
The evidence to support directly harmful effect of the microbiota on the mitochondria 
is noteworthy. Individuals with IBD have higher levels of anaerobic sulphate reducing 
bacteria, which can produce metabolites that can damage the mitochondria, inhibit 
cytochrome C and short chain fatty acid oxidation47. Within the gut flora, several 
clinically relevant pathogens including enteropathogenic E. coli 48 Helicobacter pylori 
49 and Salmonella typhimurium 50 target effector proteins to the mitochondria. 




Infection with Citrobacter rodentium has been shown to disrupt mitochondrial function 
and structure in mice 51. These lines of evidence suggest that the gut mitochondria 
occupy a distinct position as they are more exposed to damaging luminal factors, 
more so than in other tissues. Hence, it follows that different protective mechanisms 
are shaped to counter this challenge. In a proteomic analysis across 14 different 
mouse tissues, Pagliarini et al., demonstrated that intestinal epithelial mitochondria 
have a distinct proteomic profile and notably, have higher expression of ABC 
transporters 52. MDR1 (although part of the ABC superfamily) is not expressed on the 
mitochondria membrane53 but the closely analogous functions of these transporters 
highlight the importance of this protective role for the mitochondria in the gut. 
 
Beyond the microbiota, the role of luminal mitochondrial toxins as triggers in IBD is 
unknown but seems plausible. Findings from Parkinson’s disease (PD), a condition 
characterized by marked mitophagy impairment 54,55 provides insight into how this 
might work in IBD pathogenesis. Here an environmental mitochondrial toxin, N-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) represents a clear trigger for 
clinical PD. Like rotenone, MPTP is a complex I inhibitor of the electron transport 
chain that can induce acute PD that is indistinguishable from idiopathic PD56-58. 
Current literature suggests that rotenone may possess potential effects on the direct 
aggregation of protein aggregates such as α-synuclein (SNCA), ubiquitin and 
GAPDH; alterations of dopamine metabolism; and microglial activation via NFKB 
activation26. There maybe off-target actions too but given its dominant effect on 
mitochondria respiratory function, these may be difficult to detect. Even though the 
role for autophagy in general is clearly established in IBD, mitophagy has not yet 
been fully studied in this context 5,59. Strikingly and on further analysis however, 
genes involved in mitophagy (PARK7 chr1p36; p=4.8x10-9 for UC; and LRRK2 




chr12q12; p=6.2x10-21 for CD) are strongly associated with IBD in GWA studies. In 
parallel, defective mitophagy has been demonstrated in colonic epithelial cells 
derived from Irgm1-deficient mice, implicating this pathway in another IBD- associate 
gene polymorphism23. Like the virus-plus-susceptibility gene interaction that 
determines CD susceptibility as proposed by Cadwell et al. in 2010, we put forward 
the concept of mitochondrial toxin-plus-genetic susceptibility60. In this regard, we 
show that rotenone can accelerate the development of spontaneous colitis in the 
susceptible mdr1a-deficient model and in acute-induced DSS colitis, a setting when a 
second ‘hit’ along with rotenone exacerbates the severity of colitis. We believe that 
this is the first description of such kind although the protective effects of 
mitochondrial specific anti-oxidant (MitoQ) and more generally, anti-oxidants such as 
ascorbic acid have been described in experimental colitis29,30 61.  
 
Mitochondrial dysfunction via ROS production is a major mediator of inflammation 
and can directly modulate the NLRP3 inflammasome, NFΚB and MAPK signalling 
pathways62,63. Mitochondrial ROS also promote the cytosolic release of mtDNA, 
which mediates NLRP3 inflammasome activation and can directly trigger TLR9 
signalling on neutrophils64-66. Accumulation of dysfunctional mitochondria perpetuate 
the production of mROS, amplifying innate inflammatory responses such as type I 
interferon67 and endotoxin induced IL-1β production68. Mitochondrial ROS inhibits 
autophagy, the major process for removal of damaged mitochondria64. Defective 
autophagy in turn allows for the escape of pro-inflammatory mitochondrial DAMPs 66 
65. Our published colonic microarray study showing that gene-sets regulating the 
mitochondria (p=4.7×10−25) and oxido-reductase functions (p=1.4×10−13) were most 
differentially expressed comparing distal (where UC invariably affects) vs. proximal 
colon in UC. Further in silico analyses showed a negative correlation between MDR1 




and SOD2, and our data showing increased susceptibility to DSS colitis following 
intestinal epithelial specific deletion of the SOD2 gene strongly supports the causal 
importance of ROS-detoxification.  
 
IBD pathogenesis is complex and encompasses multiple factors, which may trigger 
disease onset, heighten susceptibility, potentiate severity and/or promulgate non-
resolution of inflammation. These factors combine to shape the many phenotypes of 
IBD. In this context, our data importantly highlight the mitochondria’s contribution as 
a new ‘jigsaw’ piece, a hitherto underexplored focus within this complex framework of 
factors. Specific pharmacologic MDR1 augmentation is a translational challenge due 
to induction of drug resistance as one known problem. However, our studies open up 
a new landscape of potential therapeutic approaches targeting downstream effects of 
mROS-DAMP, cellular bioenergetics and mitophagy as clear examples. Furthermore, 
we show that 5% of genes highlighted by IBD GWA studies are functionally linked to 
the maintenance of mitochondria health. Hence, the focus on mitochondrial 
dysfunction has broad translational applications, which will lead to many new 
mechanistic perspectives and therapeutic opportunities in IBD. 
 
Materials and Methods 
Mouse  
The FVB/129 mdr1a-/- and wild type mouse lines were purchased from Taconic. 
C57/BL6 mice carrying floxed allele flanking SOD2 gene was provided by Dr 
Shimizu, Chiba University, Japan and re-derived in University of Edinburgh. Villin-Cre 
recombinase C57/BL6 mice were purchased from Jackson laboratory. All colonies 
were maintained in specific pathogen free conditions (specifically Helicobacter-free) 




in University of Edinburgh.  Il10-deficient mice were maintained at University of North 
Carolina, Chapel Hill.  
 
Electron microscopy 
Mouse or human colonic samples were flushed with sterile phosphate buffered saline 
(PBS) and immediately transferred into 3% EM grade glutaraldehyde solution in 0.1M 
Sodium Cacodylate buffer, pH 7.3, for 2 hours before further processing. For 
quantification of abnormal mitochondria, viable cells with 5 or more abnormal 
mitochondria were classified as ‘abnormal’. A percentage against total number of 
IECs (minimum of 100 IECs in >5 images) was calculated per mouse. 
 
Mitochondria studies 
Mitochondria from CECs or mouse tissues were performed using Dounce 
homogenisers (30-40 strokes in 2 different gradients of homogenisers) extracted 
using Mitochondria Isolation Kit (Sigma-Aldrich, MITOISO1). For JC-1 assay, the 
mitochondria pellets were re-suspended in 100µl storage buffer + 1900µl JC-1 assay 
buffer + JC-1. Mitochondria suspensions were placed in clear-bottom black 96 wells 
plate: untreated, Antimycin 10µg/ml, rotenone 10µM and CCCP 10µM. JC-1 
fluorescence was measured using the plate reader at 590nM. The rate of 
mitochondria membrane depolarisation was measured as the loss of JC-1 
fluorescence after 1 hour. Measurements were normalised to the untreated group. 
For mROS studies, T84 CECs were plated and grown in 96 well tissue culture plates 
for at least 24-48 hours and to ~70% confluence. Cells were cultured in MitoSOX 
(2.5µM) or mitotracker Green (100nM) for 30 minutes and then washed in pre-
warmed PBS before further culture with Antimycin (20µg/ml), rotenone (10µM) or 
CCCP (10µM). Relative fluorescence (RF) was quantified using the plate reader at 




Ex/Em 510/580 and 490/516 for MitoSOX and Mitotracker Green respectively. 
MitoSOX/MitoGreen RF readings were normalised to untreated MitoSOX/Mitotracker 
Green cells only. 
 
Cellular energetics studies 
Colon and ileum were harvested and placed in DMEM/F12 medium. A 3x3mm 
intestinal section was cut and mounted in Seahorse XF24 culture plate with the 
apical side of the lumen orientated upwards and maintained in position by an Islet 
Microcapture screen. The explants were washed twice with Seahorse Assay Media, 
supplemented with 1mM Pyruvate and 10mM Glucose (pH 7.4 at 37°C).  These 
explants were placed into Seahorse analyzer within 1 hour of tissue harvest. We 
measured oxygen consumption rate (OCR) following addition antimycin/rotenone; 
providing mitochondrial function. The raw data were normalised to protein content 
using the Bradford quantification. T84 shMDR1 and shCtrl CECs were plated on 
Seahorse XF 24 cell culture plates. For the mitochondria stress test oligomycin was 
added added at 2µM, followed by 1µM FCCP then antimycin and rotenone (1µM 
each). Data was normalised to protein content measured by sulforhodamine B 
staining (Sigma S1402) to adjust for cell density. 
 
Induction and histologic grading of colitis 
Colonic rotenone or vehicle were administered using a flexible rectal tube following 
brief general anaesthesia with isofluorane. A volume of 500µl were used in a head-
down position for at least 2 minutes before removal of anaesthesia and then 
immediately check for any complications. The rotenone concentration of 100μM 
(volume of 500μl) equates to approximately 1mg/kg. In prior optimisation, we have 




tested that this volume completely filled the mouse colon to provide total exposure. 
Acute colitis was induced by 2-3% DSS (MP Biomedicals Ltd) in drinking water ad 
libitum for 7-10 days. Mice were monitored daily for weights, presence of diarrhoea 
and blood. In chronic rotenone treatment, mice were assessed at the end of every 
week. Specifically, we quantified stool consistency: Well-formed/normal = 0, 
Pasty/semi-formed = 1, Pasty = 2, Diarrhoea that does not adhere to anus = 3, 
Diarrhoea that adheres to anus = 4. For histology, each colonic sample was graded 
semi-quantitatively (Scores 0-3 per component): A. Degree of epithelial hyperplasia 
and goblet cell depletion. B. Leukocyte infiltration in the lamina propria. C. Area of 
tissue affected. D. Presence of markers of severe inflammation (such as crypt 
abscesses, submucosal inflammation and presence of ulcers). For colitis scores, the 
mean of proximal and distal colon scores was calculated. 
 
Quantification of mitochondrial DNA 
Plasma samples were obtained by cardiac puncture following CO2 euthanasia. 
Following sampling, blood samples were spun at 5 000x G for 10 minutes at 4C. 
DNA was extracted using Qiagen DNA Blood mini kit. Primer sequences for 
Cytochrome C oxidase sub-unit I (mCOI, Forward 5-GCCCCAGATATAG-CATTCCC-
3; Reverse, 5-GTTCATCCTGTTCCTGCTCC-3) with qPCR performed using 2x 
SYBR Green Fast mix (Applied Biosystems).  qPCR reactions were conducted in an 
ABI7900 Fast Real-Time PCR System (Applied Biosystems) with the following 
thermal profile: 1 cycle 95C for 20 sec; 40 cycles of 95C for 3 sec and 60C for 30 
sec. mtDNA levels were quantified based on the following calculation: c = Q × 
VDNA/VPCR × 1/Vext;  where c is the concentration of DNA in plasma (copies/µl); Q is 
the quantity (number of copies) of DNA determined by the qPCR system; VDNA is the 
total volume of eluted plasma DNA solution obtained after extraction (40µl); VPCR is 




the volume of plasma DNA used for PCR (40µl); and Vext is the volume of plasma 
extracted (200µl).  Quantification was achieved relative to a known concentration of 
PCR amplicon obtained from DNA extracted from mouse CEC mitochondria using 
method previously reported.  
 
Microarray dataset and analysis 
Full detail of tissue acquisition and process are previously detailed 13. The whole data 
set is available at Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/ 
(accessed 18 July 2008)6) accession: GSE11223 and GSE20881.  
 
Genetic analyses 
The presented data was derived from the meta-analysis of all European ancestry IBD 
patients vs. European controls 6. Analysis was done in R 3.2.2 (R Foundation for 
Statistical Computing, Vienna, Austria) using the Genomic Ranges package33. The 
UCSC hg19 Known Gene transcripts were filtered to keep only those with an 
associated Entrez Gene ID. For each Gene ID the earliest start and latest end 
position was taken from all of the transcripts for that gene. All p values within 100kb 
of each range were then associated with the respective Gene ID.  
 
shRNA knockdown studies and transfection 
T84 cells (purchased from ATCC) cells expressing MDR1 were transfected with 
MDR1 and control shRNA plasmids (SABiosciences) and selected using G418 
(600ug/ml). Cells were cultured in DMEM/F12medium with 10% foetal calf serum, 
100U/ml penicillin and 100ug/ml streptomycin. GFP-LC3 plasmid was transfected by 
Lipofectamine method (1:2 ratio) with GFP-plasmid controls to confirm transfection 
efficiency. Transfection was carried out on shMDR1 and shCtrl CECs grown on glass 




coverslips, which were then fixed with 4% paraformaldehyde and then viewed under 
fluorescence microscope. 
 
Colonic epithelial cell isolation 
Colons were removed and immediately placed in cold sterile PBS. Colons were 
opened longitudinally and further washed with buffer (154mM NaCl + 1mM 
dithiothreitol, DTT) three times. These were then placed in 5mL dissociation buffer 
(130mM NaCl, 1mM Na2EDTA, 10mM HEPES, 10% FCS, 1mM DTT) in a bijou and 
placed on a shaker at 140rpm at 37oC for 15 mins. Dissociated cells were placed in 
15mL Falcon tube on ice. Incubation in dissociation buffer was repeated with another 
2 x 5mL. Dissociated cells were spun at 2,500rpm for 10min at 4°C. Pellet was 
washed with PBS, spun at 5000rpm for 5min at 4°C. 
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Figure 1. Damaged mitochondria accumulate within mdr1a-deficient colonic 
epithelium: (a) Representative TEM (n=6 per group) of colonic epithelium. Scale bar 
2µm. Yellow arrows denoting damaged mitochondria. (b) Quantitative analyses of 
CEC containing damaged mitochondria (n=6/group). (c) Representative H&E and 
immunohistochemistry of colon (p62, PINK-1, SOD2 and VDAC) (n=6/group). (d) 
Loss of mitochondria membrane potential, JC-1 fluorescence in isolated 
mitochondria (n=6/group) (e) Plasma qPCR of mitochondrial DNA mdr1a-/- mice with 
colitis vs. no colitis (n=8/group). WT – wild-type. All data represent mean± SEM. 
 
Figure 2. MDR1 deficiency results in mitochondria dysfunction: (a) Oxygen 
consumption rate, OCR (pmol/minute) in primary colonic explant in mdr1a-deficient 
vs. WT respectively (n=4). (b) Spare respiratory capacity (SRC) of T84 shMDRI and 
shCtrl (5 replicates). (c) Normalised MitoSOX/Mitotracker Green fluorescence T84 
shMDR1 vs. shCtrl, (n=11/group, representative of 3 independent experiments.  (d) 
Relative MitoSOX/Mitotracker Green fluorescence to respective untreated group in 
T84 shMDR1 vs. shCtrl (n=8/treatment group, representative of 3 independent 
experiments).  (e) Quantification of GFP-LC3 shMDR1 vs. shCtrl (n=12 slides/group). 
%GFP-LC3+ve cells/number of cells in 10 fields (X40 microscopy). All data represent 
mean± SEM. 
 
Figure 3. Experimental induction of mROS accelerates spontaneous colitis in 
mdr1a-deficiency and in acute DSS-colitis: (a) Experimental protocol of 4-week 
colonic administration of rotenone vs. vehicle (3x/week). (b) Prevalence of clinical 




colitis in rotenone vs. vehicle treated mdr1a-/- at weekly intervals (n=18 and 15 mice 
treated with rotenone and vehicle respectively).   (c) Stool consistency 
measurements in rotenone vs. vehicle treated mdr1a-/- at weekly intervals. (d) 
Representative images of mdr1a-/- and WT whole colons treated with colonic 
rotenone. (e) Histology scores of rotenone vs. vehicle treated mdr1a-/- colons. (f) 
Representative H&E distal and proximal colons; and histology scores of rotenone vs. 
vehicle treated mdr1a-/-, black scale bars 100 µm.  (g) Experimental protocol of 
colonic rotenone vs. vehicle – 3 times during 7-day 2% DSS in drinking water. (h) 
Daily percentage of change from initial weight in rotenone vs. vehicle treated mdr1a-/- 
acute DSS colitis (n=7/group). (i, j) Representative histology scores and H&E colons 
of rotenone vs. vehicle treated mdr1a-/- (n=7/group) in acute DSS colitis, black scale 
bar 50µm. All data represent mean± SEM. 
 
Figure 4. Inhibition of mitochondria ROS effects attenuates and promotes 
recovery from colitis: (a) Experimental protocol of 4-week colonic administration of 
rotenone vs. vehicle vs. MQ (3x/week) in mdr1a-/- with established chronic colitis. (b) 
Stool consistency measurements in rotenone vs. vehicle treated vs. MQ in mdr1a-/- at 
weekly intervals. (c) Histology colitis scores of rotenone vs. vehicle vs. MQ vs. non-
colitic mdr1a-/- mice. (d) Representative whole colons and spleen sizes of and H&E of 
rotenone vs. vehicle vs. MQ vs. non-colitic mdr1a-/- mice. (e) Experimental protocol of 
colonic MQ vs. vehicle – 3x administrations during 7-day 2% DSS colitis protocol. (f, 
g) Daily percentages change from initial weight clinical colitis in MQ vs. vehicle in 
mdr1a-/- (n=6/group) and and WT mice (n=6/group) respectively. (h) Histology colitis 
scores in MQ vs. vehicle treated mdr1a-/- and WT mice, scale bar 50µm. (i) 
Experimental protocol of colonic MQ vs. vehicle treatment after 5 days of 2% DSS 




colitis protocol in WT mice. (j) Daily percentages of change from initial weight in MQ 
vs. vehicle treated WT, (n=8/7 respectively). All data represent mean± SEM. 
 
Figure 5. MDR1 and SOD2 genes are differentially expressed in human IBD and 
intestinal epithelial specific deletion of SOD2 leads to increased susceptibility 
to experimental colitis: (a-b) In silico analysis of MDR1 and SOD2 from 120 IBD 
patients (67 UC, 53 CD, 17 non-IBD colitis and 31 healthy controls); IBD-Inf = 
Inflamed IBD gut biopsies, IBD-Non-Inf = Non-inflamed IBD gut biopsies; Control-Inf 
= Non-IBD colitis and Control-Non-Infl =Non-inflamed gut biopsies from non-IBD 
individuals. (c) Spearman’s correlation test of MDR1 and SOD2 expression in 120 
IBD patients. (d) Representative immunohistochemistry and Western blotting of 
SOD2 of colons (a) of SOD2IEC-KO and SOD2flox/flox of CECs, black scale bars 100 µm, 
yellow arrows showing SOD2 staining. (e) Daily percentages of weight change from 
initial weight in acute 2% DSS colitis comparing SOD2IEC-KO vs. SOD2flox/flox (n=12/8 
respectively). (f) Histology colitis scores in SOD2IEC-KO vs. SOD2flox/flox mice (n=12/8 
respectively) after 2% DSS colitis. (g) Representative H&E staining in SOD2IEC-KO vs. 
SOD2flox/flox mice after 2% DSS colitis, black scale bars 100 µm. All data represent 
mean± SEM. 
 
Supplementary Figures Information 
S1. (a) Representative TEM sections of liver, ileum and lung from mdr1a-/- and WT 
mice (n=6) Scale bar 2µm. (b) TEM sections of colons from il10-/- and WT-following 3 
days of 3% DSS colitis. Orange scale bar is 2µm and white scale bar is 0.5µm. 
Yellow asterisks – denoting abnormal mitochondria. 
 




S2. (a) Western blot analyses of p62, Parkin, PINK, LC3I-II in isolated mouse CECs 
(n=3/group). (b) Quantitative PCR of mitochondria DNA normalised to nuclear 18S in 
CECs (n=6/group). (c) Immunohistochemistry of Ki67 in colon sections (n=6/group). 
Quantification in right panel, black scale bar 100µm (d) TUNEL assay (green: 
quantification in right panel), white scale bar 100µm (n=6/group). WT – wild-type. All 
data represent mean± SEM. 
 
S3. (a) (b) Quantitative PCR of MDR1 gene (triplicate) and representative Western 
blotting of MDR1 (C219) in T84 shMDRI and shCtrl. (c) Basal OCR of T84 shMDRI 
and shCtrl (5 replicates). (d) Western blotting of p62 and SOD2 and, (e) LC3I/II in 
untreated or bafilomycin (100nM for 2 hours) treated shMDR1 vs. shCtrl CECs 
(representative of 2 independent experiments). All data represent mean± SEM. 
 
S4. (a) Representative H&E colon sections following colonic treatment with rotenone 
at 1, 10 and 100µM (3x/week and harvested at Day 7; n=4/group) in WT mice. (b) 
Representative H&E colon sections and (c) histology colitis scores of mdr1a-/- and 
WT mice (n=5 in 0.25% DSS groups and n=6 in rotenone groups), black scale bar 
100µm, yellow arrows indicating leukocyte infiltration. (d) Representative TUNEL 
staining in mdr1a-/- and WT mice (n=3/group) and (e) quantification of TUNEL+ve 
CECs (green: quantification in right panel), white scale bar 100µm. (e) qPCR 
analyses of isolated CECs in rotenone vs. vehicle treated mdr1a-/- and untreated WT 
mice (n=6/group). *p<0.05 comparing vehicle vs. rotenone treatment in mdr1a-/- mice.  
All data represent mean± SEM. 
 




S5. (a) Western blotting of PARP and cleaved PARP products in T84 shMDR1 vs. 
shCtrl treated with rotenone (10µM), CCCP (10µM), Cisplatin 10ng/ml for 12 hours in 
T84 shMDR1 vs. shCtrl. (b) Live cell imaging of T84 shMDR1 vs. shCtrl treated with 
rotenone (5µM) at 0 and 24 hours. Loss of viability – rounded appearance, increased 
lucency and decreased adherence. (c) Rate of transepithelial electrical resistance 
(TEER) loss in T84 shMDR1 vs. shCtrl grown on 12-well transwell plates following 
culture with rotenone 5µM, (n=3). (d) IL-8 ELISA of T84 shMDR1 vs. shCtrl 12 hours 
following co-culture with rotenone (10µM), flagellin (10ng/ml) and bacterial CpG 
(2µM) (n=2/treatment group, representative of 2 independent experiments), 
R=rotenone, F=flagellin.  All data represent mean± SEM. 
 
S6. (a) Representative H&E staining of rotenone vs. vehicle vs. MQ vs. non-colitic 
mdr1a-/- colons. (b)  Representative H&E staining of MQ vs. vehicle following 7-day 
2% DSS colitis protocol in WT and mdr1a-/- colons, (c) Representative H&E staining 
of MQ vs. vehicle treated WT colons following 5-day 2% DSS and 5-days recovery, 
scale bar 50µm. 
 
Supplementary Material and Methods 
Immunohistochemistry, Western blotting and qPCR 
Formalin-fixed paraffin-embedded sections were stained according to standard 
immunohistochemistry protocols and Ab dilutions are available on request. Cell death 
was assessed by TdT-mediated dUTP nick end labelling (TUNEL) of formalin-fixed 
paraffin-embedded slides using in situ TUNEL cell death detection kit (Roche). We 
enumerated total TUNEL+ and Ki67+ IECs in entire colonic slide sections and data 




expressed as percentage of total IECs (>3 slides per subject). For Western blotting, 
cells were lysed with RIPA buffer, protein quantification by Bradford protocol, 20-40 
µg of total protein was applied to each lane and subjected to SDS-PAGE and 
Western blotting via enhanced chemiluminescence (Luminata Classico, Millipore). 
Total RNA was isolated from cells using RNeasy Mini kit (QIAGEN) and qPCR 
performed with SYBR Green RT-PCR Kit (Qiagen Cat # 204243) on ABI 7900 
system. Experimental groups were compared using ∆∆Ct values. Mouse KC 5-
GGCTGGGATTCACCTCAAGAA-3, 5-CTTGGGGACACCTTTTAGCATC-3; il-6 5-
GATGGATGCTACCAAACTGGA-3, 5-GGAAATTGGGGTAGGAAGGA-3; tnf-α 5-
CTGGGACAGTGACCTGGACT-3, 5-GCACCTCAGGGAAGAGTCTG-3; mouse 18S 




Anti-p62/SQSTM1 (1:1000 IHC, MBL), monoclonal anti-SOD2 (ab68155), polyclonal 
anti-SOD2 (1:50, PA5-30604 Thermoscientific), anti-VDAC (Abcam ab18988), PARP 
(Cell signalling), anti-PINK-1 (1:100 IHC, Abcam ab23707), anti-Parkin (Abcam 
ab81153), anti-Ki67 (Novo castra NCL-Ki67p), anti-TLR9 (abcam ab52967). 
Antimycin A (A8674-Sigma), Rotenone (R8875-Sigma), Carbonyl-cyanide 4-
(trifluoromethoxy) phenylhydrazone, CCCP (C2920 – Sigma), Bafilomycin (B1793-
Sigma) TLR9 antagonist ODN TTAGGG (Invivogen), Lipofectamine (ThermoFisher). 
MitoQ10 was a kind gift from Dr Mike Murphy, University of Cambridge. Mitotracker 
Green and MitoSOX (Molecular Probes). GFP-LC3 plasmid was kindly provided by 
Dr C Stevens, University of Edinburgh. IL-8 and IL-6 ELISA (Cambridge Bioscience). 
 
Mouse genotyping primers  




SOD2: LoxNeo 5-AGCTTGGCTGGACGTAA-3, MnSOD#42 5-CGAGGGGCATCT 
AGTGGAGAA-3; P2 5-TTAGGGCTCAGGTTTGTCCAGAA-3; Flox-allele 358 bp, 
wild-type 500 bp; 95C for 5 mins, 32 cycles of 94C for 1 min, 58C for 1 min, 72C for 2 
mins and finally 72C for 10 mins. IMR 1878 5-GTGTGGGACAGAGAACAAACC-3, 
IMR 1879 5-ACATCTTCAGGTTCTGCGGG-3; 94C for 3 mins, 35 cycles of 94C for 
30 seconds, 64C for 1 min, 72C for 1.5 min and finally 72C for 2 mins; villin-Cre 
transgene 1100 bp. 
Table S6: Genes involved in mitochondria function (using gene-set defined by term 
GO:0005739) within subset of 574 genes within 100 kb of loci with genome wide 
statistical significant association with inflammatory bowel disease (p<5 x 10-8). 






Gene Gene ID P-value Protein Name 
SLC25A28 81894 1.70 x 10-26 Mitoferrin-2 
VARS 7407 4.83 x 10-26 Valine--tRNA ligase 
RNF5 6048 9.47 x 10-24 E3 ubiquitin-protein ligase RNF5 
HSPA1A 3303 1.88 x 10-23 Heat shock 70 kDa protein 1A/1B 
HSPA1B 3304 1.88 x 10-23 Heat shock 70 kDa protein 1A/1B 
HSPA1L 3305 1.88 x 10-23 Heat shock 70 kDa protein 1-like 
TAP1 6890 2.78 x 10-21 Antigen peptide transporter 1 
GPX1 2876 2.40 x 10-20 Glutathione peroxidase 1 
SLC22A4 6583 7.07 x 10-17 Solute carrier family 22 member 4 
PLA2G2A 5320 2.31 x 10-16 Phospholipase A2, membrane associated 
MCCD1 401250 4.56 x 10-16 Mitochondrial coiled-coil domain protein 1 
STARD3 10948 1.35 x 10-15 StAR-related lipid transfer protein 3 
LRRK2 120892 3.18 x 10-15 Leucine-rich repeat serine/threonine-protein 
kinase 2 
DLD 1738 4.50 x 10-14 Dihydrolipoyl dehydrogenase, mitochondrial 
STAT3 6774 2.16 x 10-12 Signal transducer and activator of transcription 
PTRF 284119 2.16 x 10-12 Polymerase I and transcript release factor 
GPX4 2879 2.37 x 10-11 Phospholipid hydroperoxide glutathione 
peroxidase, mitochondrial 
TUFM 7284 3.86 x 10-10 Elongation factor Tu, mitochondrial 
PARK7 11315 7.36 x 10-10 Protein DJ-1 
NDUFAF3 25915 7.92 x 10-10 NADH dehydrogenase [ubiquinone]1 alpha 
subcomplex assembly factor 3 
SLC25A20 788 1.06 x 10-9 Mitochondrial carnitine/acylcarnitine carrier 
protein 
ATG5 9474 1.26 x 10-9 Autophagy protein 5 
TRIM39 56658 1.46 x 10-9 E3 ubiquitin-protein ligase TRIM39 
C6orf136 221545 2.77 x 10-9 Uncharacterized protein C6orf136 
TRIM31 11074 1.02 x 10-8 E3 ubiquitin-protein ligase TRIM31 
SDHC 6391 1.08 x 10-8 Succinate dehydrogenase cytochrome b560 
subunit, mitochondrial 
UQCR10 29796 4.54 x 10-8 Cytochrome b-c1 complex subunit 9 
VARS2 57176 1.21 x 10-9 Valine--tRNA ligase, mitochondrial 
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